Patent: 9,810,696
✉ Email this page to a colleague
Summary for Patent: 9,810,696
| Title: | PGLYRP2 biomarker in idiopathic pneumonia syndrome |
| Abstract: | A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value. |
| Inventor(s): | Chance; Mark (Chagrin Falls, OH), Cooke; Kenneth (Solon, OH), Schlatzer; Daniela (Lakewood, OH) |
| Assignee: | Case Western Reserve University (Cleveland, OH) |
| Application Number: | 14/571,067 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,810,696
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2029-06-01 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2029-06-01 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2029-06-01 |
| Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2029-06-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
